Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant durvalumab with chemotherapy and immune-modulatory radiotherapy for resectable stage III N2 NSCLC
2023-504536-18-00Phase 2Authorised
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jul 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, pemetrexed, paclitaxel, carboplatin, vinorelbine and 2 more in non-small cell lung cancer (NSCLC), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Event-free survival at 12 months. Planned start Jul 2024; status: authorised.
02
Drugs
durvalumabpemetrexedpaclitaxelcarboplatinvinorelbine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-504536-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504536-18-00.